{"id":2935,"date":"2015-05-02T07:50:36","date_gmt":"2015-05-02T07:50:36","guid":{"rendered":"http:\/\/biomedpharmajournal.org\/?p=2935"},"modified":"2016-09-06T05:25:37","modified_gmt":"2016-09-06T05:25:37","slug":"oxidative-stress-and-other-biochemical-parameters-in-hypertension-of-elderly-males","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol7no1\/oxidative-stress-and-other-biochemical-parameters-in-hypertension-of-elderly-males\/","title":{"rendered":"Oxidative Stress and Other Biochemical Parameters in Hypertension of Elderly males"},"content":{"rendered":"

Introduction<\/strong><\/p>\n

Hypertension is epidemic in our society and is the most common causes for cardiovascular disease in the world. The seventh report of the United State Joint National Committee for Detection, Evaluation, and Treatment of high blood pressure recommended a new classification system for hypertension.(1)<\/sup> The Egyptian National Hypertension Survey reported on estimated prevalence of 26.3 percent (systolic blood pressure 140 mm Hg and diastolic blood pressure 90 mm Hg).(2,3)<\/sup> India is a very large populous and typical developing country. Community surveys have documented that between three and six decade, prevalence of hypertension has increased by about 30 times among urban live and about 10 times among the rural in a relaxed and natural ways. The prevalence of hypertension has increased by about 30 times among the urban population over a period of 55 years and about 10 times among the rural population over a period of 36 years.(4)<\/sup><\/p>\n

The relationship between age and hypertension has been consistently demonstrated in cross\u2013sectional survey as well as in longitudinal cohort studies conducted in western population.(5)<\/sup> Third National Health and Nutrition Examination survey (NHANES \u2013 III) which was conducted in a representative sample of 9901 non institutionalized United States civilians 18 years of age and older, the prevalence of hypertension raised with increasing age in every gender race group.(6)<\/sup> Men have a slightly higher prevalence of high blood pressure compared with women across all ethnic groups (24.7 versus 23.4 percent). Hypertension is more common in men than in women before menopause.(7)<\/sup> The prevalence and incidence of hypertension also increase with age and the prevalence of isolated systolic hypertension raised from 5% at age 60 to greater than 10% at age 70 and 24% at age 80 year.(8, 9)<\/sup><\/p>\n

Materials and Mathods<\/strong><\/p>\n

The clinical materials for present study comprised 82 male patients of hypertension admitted in G. M. and S. G. M. Hospital, S. S. Medical College, Rewa (M. P.), India. The age range was taken from 35 to 80 years. Blood samples were collected from the patients at the time of admission. Clinical investigations were performed in the Department of Biochemistry, S. S.\u00a0 Medical College, Rewa (M. P.), India. Serum glucose, protein (Total) and superoxide dismutase were estimated by GOD-POD(10)<\/sup>, biuret(11)<\/sup> and Mishra H P et al(12)<\/sup> methods respectively. Plasma malondialdehyde was estimated by Jean C D et al method (1983).(13)<\/sup> Serum electrolytes were estimated by electrolyte analyzer. Obtained data were analyzed statistically by using student \u201ct\u201d test.<\/p>\n

Observations<\/strong><\/p>\n

Table 1: Significant test between age group (35 \u2013 50 year) and (51 \u2013 65 year) in male patients of hypertension.<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
S. No.<\/strong><\/td>\nParameters<\/strong><\/td>\nMale hypertensive patients <\/strong><\/td>\nt- test<\/strong><\/td>\nP- value<\/strong><\/td>\n<\/tr>\n
35 \u2013 50 years (22)<\/strong><\/td>\n51 \u2013 65 years (30)<\/strong><\/td>\n<\/tr>\n
Mean \u00b1 SD<\/strong><\/td>\nMean \u00b1 SD<\/strong><\/td>\n<\/tr>\n
1<\/strong><\/td>\nSystolic blood pressure(mm Hg) <\/sub><\/td>\n145.91 \u00b1 2.11<\/td>\n147.8 \u00b1 3.66<\/td>\n2.169<\/td>\n< 0.05<\/td>\n<\/tr>\n
Diastolic blood pressure(mm Hg) <\/sub><\/td>\n96 \u00b1 2.47<\/td>\n97.4 \u00b1 1.67<\/td>\n2.430<\/td>\n< 0.05<\/td>\n<\/tr>\n
2<\/strong><\/td>\nSerum Sodium ions(mEq \/ L)<\/sub><\/td>\n130.98 \u00b1 1.30<\/td>\n128.40 \u00b1 2.04<\/td>\n5.201<\/td>\n< 0.001<\/td>\n<\/tr>\n
3<\/strong><\/td>\nSerum Potassium ions(mEq \/ L)<\/sub><\/td>\n5.59 \u00b1 0.21<\/td>\n6.02 \u00b1 0.17<\/td>\n8.717<\/td>\n< 0.001<\/td>\n<\/tr>\n
4<\/strong><\/td>\nSerum Glucose(mg \/ dl)<\/sub><\/td>\n116.42 \u00b1 2.13<\/td>\n118.7 \u00b1 2.02<\/td>\n3.930<\/td>\n< 0.001<\/td>\n<\/tr>\n
5<\/strong><\/td>\nSerum Protein (Total)(gm \/ dl) <\/sub><\/td>\n6.26 \u00b1 0.12<\/td>\n6.44 \u00b1 0.16<\/td>\n4.436<\/td>\n< 0.001<\/td>\n<\/tr>\n
6<\/strong><\/td>\nS- Superoxide dismutase(EU \/ mg protein \/ ml)<\/sub><\/td>\n9.91 \u00b1 0.26<\/td>\n9.71 \u00b1 0.38<\/td>\n2.379<\/td>\n< 0.05<\/td>\n<\/tr>\n
7<\/strong><\/td>\nPlasma Malondialdehyde(nano mole \/ ml)<\/sub><\/td>\n5.20 \u00b1 0.30<\/td>\n8.74 \u00b1 0.45<\/td>\n3.008<\/td>\n< 0.001<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Table 2: Significant test between age group (51 \u2013 65 year) and (66 \u2013 80 year) in male patients hypertension.<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
S. No.<\/strong><\/td>\nParameters<\/strong><\/td>\nMale hypertensive patients <\/strong><\/td>\nt- test<\/strong><\/td>\nP- value<\/strong><\/td>\n<\/tr>\n
51 \u2013 65 year (30)<\/strong><\/td>\n66 \u2013 80 years (30)<\/strong><\/td>\n<\/tr>\n
Mean \u00b1SD<\/strong><\/td>\nMean \u00b1SD<\/strong><\/td>\n<\/tr>\n
1<\/strong><\/td>\nSystolic blood pressure(mm Hg) <\/sub><\/td>\n146.8 \u00b1 3.66<\/td>\n148.76 \u00b1 3.92<\/td>\n2.002<\/td>\n< 0.05<\/td>\n<\/tr>\n
Diastolic blood pressure(mm Hg)<\/sub><\/td>\n97.4 \u00b1 1.67<\/td>\n99.47 \u00b1 3.67<\/td>\n2.812<\/td>\n<0.001<\/td>\n<\/tr>\n
2<\/strong><\/td>\nSerum Sodium ions(mEq \/ L)<\/sub><\/td>\n128.40 \u00b1 2.04<\/td>\n127.32 \u00b1 2.09<\/td>\n2.025<\/td>\n< 0.05<\/td>\n<\/tr>\n
3<\/strong><\/td>\nSerum Potassium ions(mEq \/ L)<\/sub><\/td>\n6.02 \u00b1 0.17<\/td>\n6.50 \u00b1 0.22<\/td>\n9.456<\/td>\n< 0.001<\/td>\n<\/tr>\n
4<\/strong><\/td>\nSerum Glucose(mg \/ dl)<\/sub><\/td>\n118.7 \u00b1 2.02<\/td>\n127.27 \u00b1 4.17<\/td>\n10.131<\/td>\n< 0.001<\/td>\n<\/tr>\n
5<\/strong><\/td>\nSerum Protein (Total)(gm \/ dl) <\/sub><\/td>\n6.44 \u00b1 0.16<\/td>\n6.35 \u00b1 0.12<\/td>\n2.465<\/td>\n< 0.05<\/td>\n<\/tr>\n
6<\/strong><\/td>\nS- Superoxide dismutase(EU \/ mg protein \/ ml)<\/sub><\/td>\n9.71 \u00b1 0.38<\/td>\n9.08 \u00b1 0.50<\/td>\n5.494<\/td>\n< 0.0001<\/td>\n<\/tr>\n
7<\/strong><\/td>\nPlasma Malondialdehyde(nano mole \/ ml)<\/sub><\/td>\n8.74 \u00b1 0.45<\/td>\n8.96 \u00b1 0.37<\/td>\n2.068<\/td>\n< 0.05<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Results<\/strong><\/p>\n

Table: 1<\/strong><\/p>\n

showing comparison of male hypertensive patients between ages rang 35 \u2013 50 and 51 \u2013 65 years. We are observed, highly significant (p<0.001) increased biochemical values in the form of potassium, glucose, protein (Total), and malondialdehyde in age 51 to 65 years when compared to age 35 to 50 years of male hypertensive patients. Serum sodium was decreased highly significant (p<0.001). Significantly (< 0.05) increased systolic and diastolic blood pressure and decreased serum superoxide dismutase were found in age 51 \u2013 65 years when compared to age 35 to 50 years of male hypertensive patients.<\/p>\n

Table: 2<\/strong><\/p>\n

showing comparison of male hypertensive patients between ages rang 51 \u2013 65 and 66 \u2013 80 years. Significantly (< 0.05) increased systolic blood pressure and plasma malondialdehyde and decreased sodium and protein (Total) were found in age 66 \u2013 80 years of male hypertensive patients when compared to age 51 to 65 years of male hypertensive patients. Highly significant (p<0.001) increased diastolic blood pressure, potassium and glucose were found in male hypertensive patients (age 66 to 80 years). Extremely significantly (< 0.0001) decreased superoxide dismutase was found in male hypertensive patients (age 66 to 80 years).<\/p>\n

Discussion and Conclusions<\/strong><\/p>\n

Amongst several diseases, that affects the human these days, hypertension is considered the most dreaded. Age \u2013 related increase in hypertension prevalence have also been reported in numerous other national surveys conducted in different countries at various stages of economic development.(14) <\/sup>Emerging evidence indicated that hypertension is a vascular disease associated with inflammation, induced through redox-sensitive mechanisms that are regulated by angiotensin-II. High blood pressure is linked to vascular damage, oxidative stress and inflammation. Out of the many factors implicated in hypertensive vascular disease, angiotensin-II appears to be one of the most important(15)<\/sup> and hyperglycemia also significant in hypertension.(16)<\/sup> Hypertension with hyperglycemia responsible for cardiovascular events. Angiotensin II has direct and indirect effects on insulin and its signaling pathways, providing support for the biologic mechanism underlying the benefits of renin\u2013angiotensin system, which causes hyperglycemia.(17)<\/sup> Hypertension and electrolyte abnormalities are common in alcoholics.(18)<\/sup> Nicotine can be a potent stimulus to ADH release in humans, and this may have contributed to the development of hyponatremia. It is likely, therefore, that smoking was main reason of pathophysiology of the hyponatremic-hypertensive syndrome in many patients.(19)<\/sup> Some other studies have been found similar results.(20)<\/sup><\/p>\n

Hypertension occur de novo after 60 year of age. Although this increase and should give rise to the suspicion of secondary hypertension.(21)<\/sup> High Blood Pressure” provides a new guideline for hypertension prevention and management; (1) In the persons older than 50 years, systolic blood pressure of more than 140 mm Hg is a much more important cardiovascular disease (CVD) risk factor than diastolic blood pressure; (2) The risk of CVD, beginning at 115 \/ 75 mm Hg, doubles with each increment of 20 \/ 10 mm Hg; individuals who are normotensive at 55 years of age have a 90% lifetime risk for developing hypertension.(22)<\/sup> Familial hyperkalemia and hypertension is an autosomal dominant disorder characterized by hyperkalemia, hypertension and low renin.(23)<\/sup> Abnormality in membrane Na+<\/sup>-K+<\/sup>-2Cl–<\/sup> cotransport could be responsible for the hyperkalemia. Hyponatremic hypertensive syndrome is a rare condition of renovascular hypertension characterized by electrolyte abnormality and high rennin activity.(24) <\/sup>A marked increase in urinary protein excretion showed serum protein level was decreased.(25)<\/sup> The hyponatremic hypertensive syndrome is a rare but serious complication of renovascular disease. The syndrome is characterized by hypertension and profound natriuresis, leading to body sodium and water depletion.(26)<\/sup><\/strong> These results have supported by some other workers.(27)<\/sup><\/p>\n

There are growing evidence that increased oxidative stress and associated oxidative damage are mediators of vascular injury in cardiovascular disease. Stress is intensified with the process of aging and in the elderly, this is accompanied by a more common accuracy of primary hypertension.(28)<\/sup> Malondialdehyde is the most abundant among the reactive aldehyde derived from lipid peroxidation. These aldehyde have been implicated as the causative agents in cytotoxic processes, and it is possible that aldehydes released from the cell membrane may diffuse, interact and induce oxidative modifications in other cells and in low-density lipid molecules, thereby increasing the risk of cardiovascular damage.(29)<\/sup> The upregulation of nicotinamide adenine dinucleotide phosphate (reduced NADPH) and the tubule interstitial accumulation of active T cells, macrophage, and superoxide-production cells are partly responsible for oxidative stress in several models of hypertension.(30)<\/sup> It can be concluded that oxidative stress can cause hypertension and vice versa. Superoxide dismutase and malondialdehyde markers are most important for evaluation of hypertension.<\/p>\n

References<\/strong><\/p>\n

    \n
  1. Chobanian A V, Bakris G L, Black H R et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and treatment of High blood Pressure. JAMA<\/em>. 2003; 289: 2560 \u2013 2571.<\/li>\n
  2. Ibrahim MM, Rizk H, Appel L J, et al. Hypertension, prevalence, treatment, and control in Egypt; result from the Egyptian National Hypertension Project. Hypertension<\/em>. 1995; 26 (6 Pt 1) 886 \u2013 890.<\/li>\n
  3. Ashour Z, et al. The Eygyption National Hypertension Project (NHP). Design and rational. The NHP investigation team. Hypertension.<\/em> 1995; 26 (6 pt 1): 880 \u2013 885.<\/li>\n
  4. Das S. K, et al. Study of urban community survey in India: growing trend of high prevalence of hypertension in a developing country. Int J Med Sci<\/em>. 2005; 2 (2): 70 \u2013 78.<\/li>\n
  5. National Centre for Health Statistics. Hypertension among Mexican American United States, 1982 \u2013 1984 and 1988 \u2013 1991. MMWR<\/em>. 1995; 44: 635 \u2013 639.<\/li>\n
  6. Jones C A, McQuillan G M, Kusek J W et al. Serum creatinine levels in the U S population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis.<\/em> 2000; 35: 178.<\/li>\n
  7. Staessen J A, Van der Heijden-Spek J J, Safar M S, et al. Menopause and the characterstics of the large arteries in a population study. J Hum Hypertens<\/em>. 2001; 15: 511 \u2013 518.<\/li>\n
  8. Staessen J, Mery A, Fagard R. Isolated systolic hypertension in the elderly. J Hypertens<\/em>. 1990; 8: 393 \u2013 404.<\/li>\n
  9. Van Leer E M, Scinell J C, Kromhout D. Levels and trends in blood pressure and prevalence and treatment of hypertension in the Netherlands, 1987-1991. Am J Prev Med.<\/em> 1994; 10: 194 \u2013 199.<\/li>\n
  10. Young D S, et al. Clinical Chemistry<\/em>. 1975; 21: 1D.<\/li>\n
  11. Henri R J, et al. \u2018Clinical Chemistry-Principle and Technics\u2019. Harper & Row, II Edn. 1974.<\/li>\n
  12. Mishra H P, fridovich I. The role of superoxide anion in the autoxidation of epinephrine and simple assay for superoxide dismutase. J Bio Chem.<\/em> 1972; 247: 3170 \u2013 3175.<\/li>\n
  13. Jean C D, Maryse T, Marie J F. Plasma malondialdehyde levels during myocardial infarction. Clinica Chimica Acta.<\/em> 1983; 129: 319 – 22.<\/li>\n
  14. Ibrahim MM, Rizk H, Appel L J, et al. Hypertension, prevalence, treatment, and control in Egypt; result from the Egyptian National Hypertension Project. Hypertension.<\/em> 1995; 26 (6 Pt 1) 886 \u2013 890.<\/li>\n
  15. Touyz R M. Reactive oxygen species in vascular biology: Role in arterial hypertension. Egypte Rest Cardiovasc Ther.<\/em> 2003; 1 (1): 91 \u2013 106.<\/li>\n
  16. Anne-Safie Furberg, Inger Thune. Metabolic abnormalities (hypertension, hyperglycemic and overweight) lifestyle (high-energy intake and physical inactivity) and endometrial cancer risk in a Norwegian Cohort. Inter J Can<\/em>. 2003; 104 (6): 669 \u2013 676.<\/li>\n
  17. Vivian A Fonseca. Insuline resistance, diabetes hypertension, and renin-angiotensine system inhibition: Reducing risk for cardiovascular disease. J Clin Hypertens.<\/em> 2006; 8(10): 713 \u2013 720.<\/li>\n
  18. George Kaysen, Robert H Noth. The effects of alcohol on blood pressure and electrolytes. MCNA<\/em>. 1984; 68 (1): p 221.<\/li>\n
  19. Mamta Agrawal, Relvin L Linn, Mark Richards, M Gary Nicholls. Hyponatremia-hypertensive syndrome with renal ischemia. Hypertension.<\/em> 1999; 33: 1020 \u2013 1024.<\/li>\n
  20. Hussain M K, Frantz A G, Ciarochi F, Robinson A G. Nicotine-stimulated release of neurophysin and vasopressin in human. J Clin Endocrinol Metab<\/em>. 1975; 41: 1113 \u2013 1117.<\/li>\n
  21. Franz H, Messerli. Hypertension in special population: Edward D Frohlich. Essential hypertension. MCNA.<\/em> 1997; 81(6): 1337.<\/li>\n
  22. Arum V Chobanian, Geoge L Bakris, Hemy R Bloak, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA<\/em>. 2003; 289: 2560 \u2013 2571.<\/li>\n
  23. Haim Mayan, Gabriel Munter, et al. Hypercalceuria in familial hyperkalemia and hypertension accompanies hyperkalemia and precedes hypertension: Description of a large family with the Q 565 E WNK4 mutation. The J Clin Endo and Metab.<\/em> 2004; 89 (8): 4025 \u2013 4030.<\/li>\n
  24. Stiefel Pablo, Garcia-Morillo Salvador, et al. Gordon\u2019s syndrome: Increased maximal rate of Na-K-Cl contraport and erythrocyte membrane replacement of sphingomyelin by phophatidylethanolamine. J hypertension.<\/em> 2000; 18 (9): 1327 \u2013 1330.<\/li>\n
  25. Remuzzi A, Schieppati A, Battaglia C, et al. Angiotensin-converting enzyme inhibition ameliorates the defect in glomerular size selectivity in hyponatremic hypertensive syndrome. Am J Kidney Dis.<\/em> 1989; 14 (3): 170 \u2013 177.<\/li>\n
  26. Browne W L<\/em>, Nair B. Hyponatremic-hypertensive\u00a0syndrome<\/em>\u00a0associated with renovascular\u00a0hypertension.<\/em> J Postgrad Med.<\/em>\u00a02007; <\/em>53: 41 \u2013 43.<\/li>\n
  27. Eugenia Hopps, Rosalia Lo Presti, Gregorio Caimi. Pathophysiology of polymorphonuclear leukocyte in arterial hypertension. Clin Hemato Microcirculation.<\/em> 2009; 41 (3): 209 \u2013 218.<\/li>\n
  28. Zalba G, Mareno M U, et al. Oxidative stress in arterial hypertension: Role of NAD(P)H oxidase. Hypertension.<\/em> 2001; 38: 1395 \u2013 1399.<\/li>\n
  29. Steinberg D, Parthusarathy S, Carew T E, Khoo J C, Witztum J L. Beyond cholesterol: Modification of low-density lipoprotein that increase its atherogenicity. N Engl J Med.<\/em> 1989; 320: 915 \u2013 924.<\/li>\n
  30. Nosratola D Vaziri, Michael Discus, Natham D Ho, Lalch Boroujerdi-Rad, Ram K Sindhu. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney International.<\/em> 2003; 63: 179 \u2013 185.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Introduction Hypertension is epidemic in our society and is the […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[],"class_list":["post-2935","post","type-post","status-publish","format-standard","hentry","category-vol7no1"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/2935","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=2935"}],"version-history":[{"count":8,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/2935\/revisions"}],"predecessor-version":[{"id":8499,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/2935\/revisions\/8499"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=2935"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=2935"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=2935"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}